The efficacy and the utility of switching into glucagon like peptide-1 receptor agonist plus basal insulin therapy in type 2 diabetic patients treated with Basal-Bolus therapy.
Not Applicable
Recruiting
- Conditions
- Type 2 diabetes
- Registration Number
- JPRN-UMIN000032665
- Lead Sponsor
- Department of Endocrinology, Nippon Medical School Chiba Hokusoh Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
Type 1 diabetes with severe liver disease, severe renal disease or severe heart disease with any carcinoma under pregnancy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method the characteristics of the patient who can successfully switch the treatment efficacy(Diabetes treatment satisfaction questionnaire: DTSQ)
- Secondary Outcome Measures
Name Time Method glycemic control(continuous glucose monitoring) Urinary albumin concentration, Urinary L-FABP concentration